This trial will test a new drug for people with cervical cancer that has progressed despite other treatment. Researchers will evaluate how well the drug works and how safe it is.
1 Primary · 15 Secondary · Reporting Duration: Time from first treatment to planned final assessment at approximately 2 years
146 Total Participants · 1 Treatment Group
Primary Treatment: Bintrafusp alfa · No Placebo Group · Phase 2
Age 18+ · Female Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: